Rock Point Advisors LLC Takes $2.21 Million Position in Boston Scientific Corporation $BSX

Rock Point Advisors LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,163 shares of the medical equipment provider’s stock, valued at approximately $2,209,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Meridian Wealth Management LLC boosted its holdings in shares of Boston Scientific by 162.3% during the fourth quarter. Meridian Wealth Management LLC now owns 14,553 shares of the medical equipment provider’s stock valued at $1,388,000 after acquiring an additional 9,005 shares during the period. Strategic Planning Group LLC boosted its holdings in shares of Boston Scientific by 18.6% during the fourth quarter. Strategic Planning Group LLC now owns 53,388 shares of the medical equipment provider’s stock valued at $5,091,000 after acquiring an additional 8,358 shares during the period. AG2R LA Mondiale Gestion D Actifs boosted its holdings in shares of Boston Scientific by 6.8% during the fourth quarter. AG2R LA Mondiale Gestion D Actifs now owns 59,544 shares of the medical equipment provider’s stock valued at $5,678,000 after acquiring an additional 3,812 shares during the period. Swiss Life Asset Management Ltd boosted its holdings in shares of Boston Scientific by 4.8% during the fourth quarter. Swiss Life Asset Management Ltd now owns 167,303 shares of the medical equipment provider’s stock valued at $15,952,000 after acquiring an additional 7,631 shares during the period. Finally, Asahi Life Asset Management CO. LTD. raised its stake in shares of Boston Scientific by 136.1% during the fourth quarter. Asahi Life Asset Management CO. LTD. now owns 6,226 shares of the medical equipment provider’s stock valued at $594,000 after purchasing an additional 3,589 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $54.12 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $64.65 and its two-hundred day moving average price is $82.68. Boston Scientific Corporation has a 52 week low of $53.15 and a 52 week high of $109.50. The stock has a market cap of $80.43 billion, a PE ratio of 22.64, a price-to-earnings-growth ratio of 0.98 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the business earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, February 2nd. Royal Bank Of Canada cut their price objective on shares of Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a research note on Thursday, April 23rd. Sanford C. Bernstein restated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Finally, Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.